Strategics back Trimtech’s protein cluster degraders with $31M: Finance Report

A U.K.-based start-up with an aggregate-selective protein degradation technology has attracted a $31 million seed round that includes strategic backers alongside founding investors Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund.

In an August 2024 paper published in Science, co-founders of Trimtech Therapeutics Ltd. described the fusion of an E3 ligase TRIM21 RING domain, which requires clustering for activation, to a tau-targeting single-domain antibody to create a genetically encoded, intracellularly expressed construct capable of selectively degrading aggregated proteins while sparing tau monomers...